BCLSI
KYTX icon

Bain Capital Life Sciences Investors’s Kyverna Therapeutics KYTX Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.7M Sell
2,885,000
-225,000
-7% -$2M 1.53% 14
2026
Q1 		$26.8M Hold
3,110,000
– – 2.42% 10
2025
Q4 		$29.2M Sell
3,110,000
-258,370
-8% -$1.92M 2.24% 10
2025
Q3 		$20.2M Hold
3,368,370
– – 1.34% 13
2025
Q2 		$10.3M Hold
3,368,370
– – 1.29% 15
2025
Q1 		$6.5M Hold
3,368,370
– – 0.96% 14
2024
Q4 		$12.6M Hold
3,368,370
– – 1.48% 12
2024
Q3 		$16.5M Hold
3,368,370
– – 1.71% 10
2024
Q2 		$25.3M Buy
3,368,370
+204,502
+6% +$3.12M 2.77% 8
2024
Q1 		$78.6M Buy
+3,163,868
New +$88.3M 6.32% 5

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bain Capital Life Sciences Investors's KYTX Position: Q2 2026 in Review

Bain Capital Life Sciences Investors reduced its Kyverna Therapeutics (KYTX) stake by 7.2% in Q2 2026, selling an estimated $2M and leaving 2,885,000 shares worth $25.7M. The position accounts for 1.53% of the portfolio, ranked #14.

Bain Capital Life Sciences Investors first reported a position in KYTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $78.6M in Q1 2024. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Bain Capital Life Sciences Investors held 2,885,000 shares of Kyverna Therapeutics worth $25.7M as of Q2 2026.
  • Bain Capital Life Sciences Investors sold 225,000 Kyverna Therapeutics shares in Q2 2026, an estimated $2M.
  • Kyverna Therapeutics made up 1.53% of Bain Capital Life Sciences Investors's portfolio in Q2 2026, its #14 holding.
  • Bain Capital Life Sciences Investors first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Bain Capital Life Sciences Investors's Kyverna Therapeutics position peaked at $78.6M in Q1 2024.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2026, filed 14 Aug 2026.